Last November, a 43-year-old financial analyst in Austin named Derek told his prescribing clinician he'd been running CJC-1295 DAC for seven straight months. No break. He felt great for the first twelve weeks, then noticed the sleep improvements fading. By month five, the recovery benefits he'd been tracking in his training log had flatlined. His IGF-1, initially bumped from 168 to 247 ng/mL, had drifted back to 202 without any dosage change. "I figured more time on meant more results," he said. "Turns out I was just burning runway."
Derek's experience is exactly why most CJC-1295 protocols are cycled rather than continuous. The standard approach: 8 to 12 weeks on, followed by 4 weeks off. The reasoning involves limiting theoretical receptor desensitization, managing cumulative IGF-1 exposure, and preserving responsiveness across repeated cycles. CJC-1295 is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients. Results vary by person.
The Case For (and Against) Taking Breaks
The GHRH receptor is a G-protein-coupled receptor, and like most receptors in that family, it is theoretically subject to desensitization with sustained stimulation. This concern sharpens with the DAC version because of its extended signaling window. Your body's natural GH release is pulsatile, not a steady drip. That matters.
A study by Veldhuis et al. (2005) in the American Journal of Physiology established that GH secretion follows an ultradian rhythm, with the largest pulses occurring during slow-wave sleep and smaller bursts throughout the day. The architecture of this pulsatility is itself regulatory: the hypothalamus alternates between GHRH stimulation and somatostatin inhibition, and this oscillation is what keeps the pituitary somatotrophs sensitive. When you layer a long-acting GHRH analog on top of that system continuously, you are, in theory, compressing the natural rest period those receptors would otherwise get.
There's also the practical problem: long-term human data on continuous CJC-1295 use at compounded doses is thin. And cumulative IGF-1 exposure remains a live conversation in longevity medicine circles. Research from Renehan et al. (2004), published in The Lancet, found a statistical association between elevated circulating IGF-1 concentrations and increased risk of certain cancers, particularly colorectal and prostate. The dose-response curve and clinical relevance at the IGF-1 levels seen in peptide protocols remain debated, but the signal is strong enough that oncologists flag it. Not panic-level, but enough to warrant paying attention.
Here's the thing, though. No large randomized trial has actually demonstrated desensitization with continuous CJC-1295 use at these doses. Some clinicians do run patients on longer continuous stretches. The conservative default remains cycled, and I think that's the right call. When the long-term data is sparse, you default to caution. Boring answer. Correct answer.
A related consideration is the hypothalamic-pituitary feedback loop itself. Sustained elevation of GH and IGF-1 increases somatostatin tone over time, a natural brake on further GH release. This is not the same thing as receptor desensitization, but the practical effect is similar: diminishing returns. Teichman et al. (2006) showed significant and sustained GH elevation over two to four weeks of CJC-1295 DAC dosing, but the study was not designed to capture what happens at the eight- or twelve-week mark. We are extrapolating. Cycling is the hedge against that gap in the evidence.
Three Cycling Patterns Worth Knowing
12 weeks on, 4 weeks off. The most common. Full benefit window, longer commitment per cycle. Run your standard CJC-1295 protocol (DAC weekly or no-DAC daily) for twelve weeks, then stop completely for four. Repeat under clinician direction. This is the pattern most clinicians default to because it maps well to the timeline where benefits appear to accumulate. Anecdotal and clinical reports consistently show that sleep quality improvements, body composition changes, and recovery gains tend to build through weeks four to ten, with some patients still seeing progressive improvement at week twelve.
8 weeks on, 4 weeks off. Better for first-timers. Shorter feedback loop makes it easier to assess whether the peptide is doing anything meaningful before you commit to a longer run. The tradeoff is less time accumulating benefits per cycle. This is also the pattern of choice when a clinician wants to evaluate tolerability, particularly for patients with borderline fasting glucose or a family history of insulin resistance, since GH and IGF-1 elevation can nudge glucose metabolism in ways that need monitoring.
12 weeks on, 8 weeks off. The conservative play for people thinking in years, not months. Maximum receptor recovery, smallest cumulative exposure. More time off than on, which bothers some people psychologically, but the math works for long-haul use. Patients running this schedule often report that subsequent cycles "hit" noticeably harder than a continuous protocol or a shorter off-period would produce. That observation aligns with the desensitization hypothesis, though it is not proof of it.
DAC and No-DAC Don't Clear the Same Way
This is where people get tripped up.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →The DAC version has a long half-life, so the signal doesn't just stop when you stop injecting. Teichman et al. (2006) reported a half-life of approximately 5.8 to 8.1 days for the DAC conjugate, meaning the signal fades across roughly the first two weeks of your off-period before fully clearing. Your effective off-period is shorter than the calendar shows. Some clinicians extend DAC off-periods by one to two weeks to compensate, and that makes sense. If you are running a 12 on / 4 off schedule with DAC, you may only be getting two genuine "clean" weeks before restarting. For some clinicians, this is fine. For others, it is an argument for 12 on / 6 off with DAC specifically.
No-DAC (also called modified GRF 1-29) clears within hours of your last dose, with an estimated half-life of roughly 30 minutes. Day one of your off-period is a genuine clean break. No residual signal to account for. This pharmacokinetic simplicity is one reason some clinicians prefer no-DAC for patients who want tight control over their cycling.
A practical distinction: because no-DAC clears fast, you get pulsatile GH release that more closely mimics the body's own rhythm. Each injection triggers a discrete pulse, and then the signal goes away. With DAC, you get a sustained tonic signal. Both approaches have advocates; neither is objectively superior for all patients. But the cycling implications are different, and your off-period planning should reflect which version you are using.
What the Off-Period Actually Feels Like
Endogenous GH and IGF-1 drift back toward your pre-cycle baseline. Most people report this takes two to four weeks to fully settle.
The first two weeks can be annoying. Sleep depth drops. Recovery slows. It's like going from a well-tuned engine back to stock. Patients who train hard sometimes describe feeling "flat" during this window, with workouts feeling more effortful and soreness lingering longer than it did on-cycle. This stabilizes by week three or four for most people. It is not a crash. It's a return to normal, and normal feels worse by comparison.
One underappreciated aspect of the off-period: your subjective experience of "normal" after a successful cycle is actually valuable clinical data. If you feel significantly worse off-cycle, it suggests the peptide was doing something meaningful. If you feel exactly the same, that is worth discussing with your clinician before committing to another round.
Some patients report mild mood changes during the first week off, likely related to the drop in sleep quality rather than a direct neurochemical effect of the peptide. Improving sleep hygiene during the off-period (consistent bedtime, cool room, no screens within an hour of sleep) can blunt the transition.
Restarting and Mid-Cycle Adjustments
If your off-period was under three months, most clinicians don't require a full titration restart. Pick up where you left off, same dose you ended on.
Longer gaps (three to six months or more) warrant a brief re-titration to see how your body responds fresh. A common approach is to restart at 50 to 75 percent of your previous working dose for the first week, then return to full dose in week two assuming no adverse response.
Mid-cycle, watch for these signals:
- Still feeling nothing by week four? Increase injection frequency (no-DAC) before bumping per-dose volume. Going from once daily to twice daily (morning and pre-bed) is a common adjustment.
- Mild water retention on DAC? Cut per-injection dose by 25 to 50%. This is the most frequent side effect that prompts a mid-cycle change. Facial puffiness and tight-fitting rings are early signals.
- Sleep disruption? Move the pre-bed dose earlier. Sometimes thirty minutes makes the difference. If you are injecting at 10:30 PM and waking at 2 AM, try 9:45 PM.
- Response tapering off between weeks 8 and 12? That's likely end-of-cycle attenuation. Transition to your off-period rather than chasing it with higher doses. This is the mistake Derek made: interpreting diminishing returns as a reason to extend the cycle instead of ending it.
Stacking Considerations During Cycles
When CJC-1295 is stacked with ipamorelin, synchronize the cycles. Start together, stop together. Partial-stack dosing (one on, one off) creates a confusing signal and makes it impossible to evaluate what's working. Both peptides act on the GH axis, so their off-periods should coincide to give the axis a genuine rest.
Non-GH peptides like BPC-157 or GHK-Cu don't need to follow the same schedule. Different mechanisms, independent timelines. BPC-157, for example, targets different receptor systems (including nitric oxide pathways) and does not contribute to GH or IGF-1 elevation. Running it during your CJC-1295 off-period is a reasonable approach for patients managing soft tissue recovery.
If you are stacking CJC-1295 with a GHRP such as hexarelin or GHRP-6, the cycling consideration becomes more important, not less. GHRPs carry their own desensitization risk, particularly hexarelin, which has shown tachyphylaxis in clinical settings within weeks of continuous use (Arvat et al., 1997, European Journal of Endocrinology). Stacking two secretagogues that both push GH output makes the argument for disciplined cycling even stronger.
Mistakes That Keep Coming Up
Running 12-plus months straight without a break (see: Derek, above). Treating the off-period as a "half-dose period" instead of a genuine stop. Stopping DAC and immediately restarting before the residual signal clears. Restarting multiple peptides at staggered intervals within the same stack, which turns your protocol into a science experiment with no controls.
Two more: failing to log subjective response (you cannot compare cycle to cycle if you don't write things down) and switching between DAC and no-DAC mid-cycle without a washout period. Pick one format per cycle. The two versions have different pharmacokinetics, different dosing frequencies, and different clearance timelines. Switching mid-cycle muddies the data and makes it nearly impossible for your clinician to interpret your response.
A less obvious mistake: adjusting other variables during the first cycle. Starting a new training program, changing your diet dramatically, beginning a new supplement stack, or altering sleep medication at the same time you start CJC-1295 means you will never know what caused any change you observe. First cycles in particular should be run against a stable baseline.
Choosing Your Pattern
Think of it like periodization in training, because that's essentially what it is.
- First cycle: 8 on / 4 off. Assess response without over-committing.
- Established responder: 12 on / 4 off for ongoing use.
- Long-term exposure concern: 12 on / 8 off.
- Seasonal athlete or trainee: Align your peptide cycle with your training block. Bulk phase or competition prep on, deload or off-season off.
For patients running CJC-1295 across multiple years, annual monitoring matters: IGF-1, fasting glucose, HbA1c, TSH, free T4, lipid panel. No published upper limit on cycle count exists, but an annual goal reassessment with your clinician is common practice. Some clinicians also track morning cortisol and insulin levels, particularly in patients over 50 or those with metabolic risk factors.
Reasons to stop entirely: active or recently diagnosed malignancy, new uncontrolled diabetes, new thyroid abnormality, persistent side effects that don't resolve across cycles, or simply reaching your goal with no need for maintenance. Pregnancy or planned pregnancy is another clear stop signal; effects of exogenous GH secretagogues on fetal development are unstudied.
The prescribing clinician directs the actual protocol.
FAQ
Do I really need to cycle CJC-1295?
The conservative default is yes, though no large randomized trial directly shows desensitization at compounded doses with continuous use. Most clinicians cycle as a precaution. Given the limited long-term data, the precaution seems warranted. The cost of cycling (a few weeks without the peptide) is low compared to the potential cost of running continuously and losing efficacy without knowing why.
What is the minimum off-period?
Four weeks is the standard minimum. Shorter off-periods exist in some protocols, but the rationale weakens quickly below that threshold. For DAC specifically, remember that one to two weeks of your off-period are occupied by residual drug clearance, so a two-week off-period may functionally be zero clean days.
Can I switch to another peptide during the off-period?
If the point of the break is letting the GH axis return to baseline, switching to another GH secretagogue defeats the purpose. Non-GH peptides (GHK-Cu, BPC-157) are fine during the off-period. Some patients use the off-period to run peptides targeting entirely different goals, like thymosin alpha-1 for immune modulation.
Will my benefits come back after the off-period?
Most users report benefits returning within the first two to four weeks of restarting. The off-period does not erase what you built. Think of it as a reset, not a reversal. Body composition changes in particular tend to hold if training and nutrition remain consistent during the off-period. Sleep and recovery benefits are more immediately tied to active dosing and may dip during the break.
Should DAC and no-DAC be cycled differently?
The structural cycle is the same (typically 12 on / 4 off). The practical difference is that DAC takes longer to functionally clear because of its longer half-life. Some clinicians extend DAC off-periods by one to two weeks to account for this. No-DAC clears fast and needs no adjustment.
How do I know if my cycle length is right?
Track your response. If benefits plateau well before week 12, a shorter cycle might suit you. If you're still improving at week 12, your clinician may consider extending the next round. Logging matters more than guessing. A simple weekly journal entry noting sleep quality (1 to 10), recovery speed, body composition observations, and any side effects gives you and your clinician something concrete to review.
Is there a maximum number of cycles?
No published limit. Annual reassessment of labs and clinical goals is the standard safeguard for indefinite cycling. Some clinicians recommend a longer break (8 to 12 weeks) every fourth or fifth cycle as an additional precaution, though this is based on clinical judgment rather than trial data.
Related Reading
---
Disclaimer: CJC-1295 is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients under a valid prescription. This article is for educational purposes and does not constitute medical advice. Individual results vary. Always consult a licensed prescribing clinician before starting any compounded peptide protocol.
Citation: Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
Citation: Veldhuis JD, Roelfsema F, Iranmanesh A, et al. Basal, pulsatile, entropic (patterned), and spiky (staccato-like) properties of ACTH secretion: impact of age, gender, and body mass index. J Clin Endocrinol Metab. 2009;94(10):4045-4052.
Citation: Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353.
Citation: Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174.